New report maps patent race shaping next-gen obesity drugs beyond GLP-1 therapies

PatentVest released a report analyzing 27 global triple-agonist obesity drug programs, highlighting a shift beyond first-generation GLP-1 treatments. Eli Lilly's retatrutide leads with near-surgical weight loss results, signaling a new competitive phase focused on intellectual property, delivery systems, and receptor engineering. The report identifies key players like Eli Lilly, Novo Nordisk, and emerging biotech firms, noting China's growing role in development. Strategic patent control and innovative delivery methods are expected to shape the future obesity drug market.